Jose Manuel Viñuela Prieto

Dr. Jose Manuel Viñuela Prieto

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2020 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
FCFrancisco Javier Candel
Francisco Javier Candel
JPJose Manuel Viñuela Prieto
Jose Manuel Viñuela Prieto
JCJ González Del Castillo
J González Del Castillo
PGP Barreiro García
P Barreiro García
MSM Fragiel Saavedra
M Fragiel Saavedra
AGA Zapatero Gaviria
A Zapatero Gaviria
Introduction. The diagnosis of SARS-CoV-2 infection is crucial for medical and public health reasons, to allow the best treatment of cases and the best control of the pandemic. Serology testing allows for the detection of asymptomatic infections and 19-COVID cases once the virus has been cleared. We analyzed the usefulness of the SARS-CoV-2 rapid test of Autobio and tried to correlate its pattern with the severity of COVID19 infection. Material and methods. We analyzed the accuracy and clinical usefulness of a point-of-care IgM and/or IgG test for SARS-CoV-2 in 35 COVID-19 patients [12 (34.3%) mild-moderate and 23 (65.7%) severe-critical] admitted to a field hospital in Madrid, as well as in 5 controls. Results. The mean time from the first day of symptoms to the antibody test was 28 days (SD: 8.7), similar according to the severity of the disease. All patients with SARS-CoV-2 PCR+ showed the corresponding IgG positivity, while these results were negative in all control individuals. A total of 26 (74%) cases also presented with positive IgM, 19 (83%) were severe-critical cases and 7 (58%) were mild-moderate cases. The IgM response lasted longer in the severe critical cases (mean: 29.7 days; SD: 8.4) compared to the moderate cases (mean: 21.2 days; SD: 2.0). Conclusions. Rapid serology tests are useful for the diagnosis of patients with COVID-19 (mainly IgG detection) and may also be correlated with the severity of the infection (based on IgM detection).

17 October 2024 in Spine
Verified
Journal Article
Open access
OCOlga Ciobanu-Caraus
Olga Ciobanu-Caraus
AGAlexandra Grob
Alexandra Grob
JRJonas Rohr
Jonas Rohr
VSVittorio Stumpo
Vittorio Stumpo
Luca RicciardiLuca Ricciardi
Luca Ricciardi
VSVictor E. Staartjes
Victor E. Staartjes
Study Design.: Heterogeneous data collection through a mix of prospective, retrospective, and ambispective methods. Objective.: To evaluate the effect of biological sex on patient-reported outcomes after spinal fusion surgery for lumbar degenerative disease. Summary of Background Data.: Current literature suggests sex differences regarding clinical outcome after spine surgery may exist. Substantial methodological heterogeneity and limited comparability of studies warrants further investigation of sex-related differences in treatment outcomes. Materials and Methods.: We analyzed patients who underwent spinal fusion with or without pedicle screw insertion for lumbar degenerative disease included within a multinational study, comprising patients from 11 centers in seven countries. Absolute values and change scores (change from preoperative baseline to postoperative follow-up) for 12-month functional impairment [Oswestry disability index (ODI)] and back and leg pain severity [numeric rating scale (NRS)] were compared between male and female patients. Minimum clinically important difference (MCID) was defined as >30% improvement. Results.: Six-hundred sixty (59%) of 1115 included patients were female. Female patients presented with significantly baseline ODI (51.5±17.2 vs. 47.8±17.9, P<0.001), back pain (6.96±2.32 vs. 6.60±2.30, P=0.010) and leg pain (6.49±2.76 vs. 6.01±2.76, P=0.005). At 12 months, female patients still reported significantly higher ODI (22.76±16.97 vs. 20.50±16.10, P=0.025), but not higher back (3.13±2.38 vs. 3.00±2.40, P=0.355) or leg pain (2.62±2.55 vs. 2.34±2.43, P=0.060). Change scores at 12 months did not differ significantly among male and female patients in ODI (∆1.31, 95% CI: -3.88 to 1.25, P=0.315), back (∆0.22, 95% CI: -0.57 to 0.12, P=0.197), and leg pain (∆0.16, 95% CI: -0.56 to 0.24, P=0.439). MCID at 12 months was achieved in 330 (77.5%) male patients and 481 (76.3%) female patients (P=0.729) for ODI. Conclusion.: Both sexes experienced a similar benefit from surgery in terms of relative improvement in scores for functional impairment and pain. Although female patients reported a higher degree of functional impairment and pain preoperatively, at 12 months only their average scores for functional impairment remained higher than those for their male counterparts, while absolute pain scores were similar for female and male patients.

19 August 2021 in Transplantation Proceedings
Verified
Journal Article
Open access
JPJose Manuel Viñuela Prieto
Jose Manuel Viñuela Prieto
MFMaria Carmen Escarpa Falcón
Maria Carmen Escarpa Falcón
FCFrancisco Javier Candel
Francisco Javier Candel
ARAlonso Mateos Rodríguez
Alonso Mateos Rodríguez
JGJuan Ignacio Torres González
Juan Ignacio Torres González
FGFrancisco del Río Gallegos
Francisco del Río Gallegos
Background: Organ and tissue recovery remains limited by several factors. This study retrospectively analyzes the factors associated with family refusal to consent to donation at a high-donor-volume Spanish hospital. Methods: Data regarding the annual number of potential donors and family refusal rates at hospital and regional levels were retrieved from 2008 to 2017. Descriptive, bivariate, and multivariate analyses were performed to detect those factors independently associated with family refusal. Results were cross-validated using the data from years 2018 and 2019 as the validation group. To explore potential inter-relations between factors a Multiple Correspondence Analysis was performed. Results: A total of 601 family interviews for petition of consent were conducted between 2008 and 2017, 531 (88.4%) resulted in acceptance and 70 (11.6%) resulted in refusal of the donation. Lesser experience of the interviewers (odds ratio [OR], 2.980; P = .001), donation after brain death (OR, 2.485; P = .013), number of interviews conducted per family (OR, 1.892; P < .001), age of the main decision maker (OR, 1.025; P = .045), and high or middle attributed cultural levels (OR, 0.142; P < .001 and OR, 0.199; P < .001 respectively) were observed to be independently associated with the family final decision. The logistic regression model displayed good predictive power for both derivation and validation cohorts, with an overall predictive accuracy of 80.9% (95% confidence interval, 0.747-0.870; P < .001) and 74.4% (95% confidence interval, 0.635-0.854; P = .001), respectively. Conclusions: Transplant coordination team members having a thorough knowledge of the family decision mechanisms may be a key factor in donation process optimization.

1 July 2019 in Journal of Hospital Infection
Verified
Journal Article
Closed access
JPJose Manuel Viñuela Prieto
Jose Manuel Viñuela Prieto
ASA.M. Soria-García
A.M. Soria-García
MGM. González-Romero
M. González-Romero
FCFrancisco Javier Candel
Francisco Javier Candel

23 October 2021 in Brain and Spine
Verified
Journal Article
Open access
JPJose Manuel Viñuela Prieto
Jose Manuel Viñuela Prieto
JSJose F. Paz Solis
Jose F. Paz Solis
AIAlberto Isla-Guerrero
Alberto Isla-Guerrero
JDJavier Díaz-de-Terán
Javier Díaz-de-Terán
MGMaría Luisa Gandía-González
María Luisa Gandía-González
Chronic pain inflicts damage in multiple spheres of patient's life and remains a challenge for health care providers. Real-world evidence derived from outcome registries represents a key aspect of the ongoing systematic assessment and future development of neurostimulation devices. The objective of the present study was to assess the long-term effectiveness of neurostimulation as a treatment for spinal chronic pain. The patients analyzed in the present study represent a singlecenter cohort of 52 individuals. Primary outcome measures included numeric pain rating scale, Beck depression index II and Oswestry disability index variation from baseline to 36-month visits. Secondary outcomes included its evaluation at 6-month, 12-month and 24-month visits. A significant improvement in targeted pain, depression and disability values were observed at 36-month follow-up (P ​< ​0.001, P ​= ​0.009 and P ​< ​0.001 respectively). Those results were consistent in the leg and back pain subgroup but not in the neck, chest and arm pain subgroup. The decrease in pain, depression and disability values happened progressively through time, with the exception of the 12-month visit, where a mild stagnation was observed. Our results suggest that spinal cord stimulation is an effective long-term treatment for spinal chronic pain in real-world conditions when applied to a variety of patients and conditions usually seen in routine practice. Nevertheless, some fluctuations may occur during treatment so prolonged follow-up periods should be considered before rendering an unsuccessful therapy diagnosis.

10 May 2021 in Viruses
Verified
Journal Article
Open access
PDF file
PBPablo M. Bàrreiro
Pablo M. Bàrreiro
FCFrancisco Javier Candel
Francisco Javier Candel
JSJuan Carlos Sanz
Juan Carlos Sanz
JMJesus San Roman Montero
Jesus San Roman Montero
MCMaría del Mar Carretero
María del Mar Carretero
AZAntonio Zapatero-Gaviria
Antonio Zapatero-Gaviria
The virological meaning of the different patterns of serology in COVID-19 has been little examined in clinical settings. Asymptomatic subjects with IgM-spike (S) and IgG-nucleocapsid (N) determinations by chemiluminescence were studied for SARS-CoV-2 shedding in respiratory secretions by transcription-mediated amplification (TMA). In subjects showing IgM-S positive and IgG-N negative, IgG-S was determined by lateral flow assay. A total of 712 individuals were tested: 30.0% presented IgM-S(+)/IgG-N(−), 25.8% had IgM-S(+)/IgG-N(+) and 44.2% had IgM-S(−)/IgG-N(+); the proportion with TMA(+) were comparable in these three groups: 12.1, 8.7 and 10.5%, respectively. In individuals with IgM-S(+)/IgG-N(−), IgG-S(+) was detected in 66.5%. The frequency of IgM-S(+)/IgG-S(−) in the total population was 10.0%, of whom 24.1% had TMA(+); the chances for TMA(+) in subjects with an IgM-S(+) alone pattern were 2.4%. Targeting of the same SARS-CoV-2 antigen seems to be better for the characterization of IgM/IgG patterns of response. IgM-S(+) alone reactivity is rare, and a small proportion is associated with viral shedding.